Why Minerva Neurosciences Is Heading Higher Today

Minerva Neurosciences (NASDAQ: NERV), a small-cap biotech, is rebounding a bit Monday after a dramatic plunge on Friday. Specifically, the drugmaker's shares are up by 16.4% as of 12:47 p.m. EDT.

Minerva's shares cratered by 72.5% on Friday in response to the late-stage failure of its lead drug candidate, roluperidone, as a treatment for symptoms associated with schizophrenia. The drug did no better than a placebo on either the study's primary endpoint of reduction in negative symptoms or a key secondary endpoint (improvement in personal and social performance measurements).

Image Source: Getty Images.

Source Fool.com